EEF2: Elongation factor 2
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Catalyzes the GTP-dependent ribosomal translocation step during translation elongation.
- Drugs that act on it: 11
- Approved: 3
- In phases 1 to 3: 8
- Sponsors: 7
Who Is On It, and How Far Along
Every drug ChEMBL records acting on EEF2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody-drug conjugate
- Protein or peptide
- Other
Approved3
Phase 32
Phase 24
Phase 12
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Beijing VDJBio Co., LTD.19%
- Innate Pharma19%
- Insys Therapeutics19%
- Menarini Group19%
- Roche19%
- Sesen Bio, Inc.19%
- Virogen Biotechnology Inc.19%
Modalities
Drugs on this target by ChEMBL molecule type.
- Antibody-drug conjugate218%
- Protein or peptide327%
- Other655%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 10 of 11 act as: Elongation factor 2 inhibitor; the rest name their own mechanism.| Tagraxofusp | Approved | Menarini Group | Protein or peptide | Inhibitor | — | 14 | Boxed warning |
| Denileukin diftitox | Approved | Beijing VDJBio Co., LTD. | Protein or peptide | Inhibitor | — | 4 | Boxed warning |
| Moxetumomab pasudotox | Approved | Innate Pharma | Antibody-drug conjugate | Inhibitor | — | 1 | Boxed warning |
| Cintredekin besudotox | Phase 3 | Insys Therapeutics | Protein or peptide | Inhibitor | — | 0 | — |
| Oportuzumab monatox | Phase 3 | Sesen Bio, Inc. | Antibody-drug conjugate | Inhibitor | — | 0 | — |
| LMB-1 | Phase 2 | — | Other | Inhibitor | — | 0 | — |
| LMB-100 | Phase 2 | Roche | Other | Disrupting agent | Elongation factor 2 disrupting agent | 0 | — |
| LMB-2 | Phase 2 | — | Other | Inhibitor | — | 0 | — |
| Resimmune | Phase 2 | Virogen Biotechnology Inc. | Other | Inhibitor | — | 0 | — |
| LMB-7 | Phase 1 | — | Other | Inhibitor | — | 0 | — |
| LMB-9 | Phase 1 | — | Other | Inhibitor | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Spinocerebellar ataxia type 26
- 0.60
- Primary cutaneous T-cell non-Hodgkin lymphoma
- 0.54
- Neoplasm
- 0.54
- Neurodegenerative disease
- 0.49
- Hydrocephalus
- 0.46
- Parkinson disease
- 0.42
- Alzheimer disease
- 0.42
- Lysosomal storage disease
- 0.41
- CD4+/CD56+ hematodermic neoplasm
- 0.41
- Neurodevelopmental disorder
- 0.40
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1795108, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P13639, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets